United States
US 12,702,715 B2
Targeted RNA degradation allows precision repurposing of protein-targeted small molecule medicines to RNA
US 12,702,715 B2 is a granted patent from the United States Patent and Trademark Office (USPTO), dated 2026-08-11. Applicant: University of Florida Research Foundation, Incorporated. Its PDF downloads from this page without an account, up to 5 a day.
- Applicant
- University of Florida Research Foundation, Incorporated
- Inventors
- Matthew D. Disney
- Publication date
- 2026-08-11
- Filing date
- 2023-01-30
- Document type
- B2 Granted patent
- Also written as
- US 12,702,715 B2 · US12702715 · 12702715
Abstract
The protein targeted medicine, Dovitinib, has been repurposed to target a non-coding RNA by using selection and computational drug design via Inforna. Selectivity was achieved for pre-miR-21 by endowing the medicine with the ability to recruit RNA quality control enzymes to cleave the target.
The opening of the abstract. The full text is in the PDF.
No account needed: 5 free downloads a day (5 left today). Batch downloads and Office Action citations need a free account.
Patent office website: United States Patent and Trademark Office (USPTO)
Look up another patent
Need many patents at once?
Paste a whole list of numbers. DownloadPatent finds the right version of each and packs the PDFs into one ZIP.
Sign up free